Medicine & Life Sciences
Protein-Tyrosine Kinases
100%
Leukemia, Myelogenous, Chronic, BCR-ABL Positive
75%
ponatinib
67%
4-methyl-N-(3-(4-methylimidazol-1-yl)-5-(trifluoromethyl)phenyl)-3-((4-pyridin-3-ylpyrimidin-2-yl)amino)benzamide
64%
Dasatinib
58%
Imatinib Mesylate
46%
Meta-Analysis
40%
Blood Vessels
30%
Survival
28%
Atherosclerosis
24%
Cell Survival
24%
Endothelial Cells
23%
Systematic Reviews
23%
Dacarbazine
20%
bosutinib
19%
Vinblastine
19%
Bleomycin
17%
Hodgkin Disease
16%
Odds Ratio
15%
Doxorubicin
14%
In Vitro Techniques
14%
Rupture
13%
Randomized Controlled Trials
10%
Biomarkers
10%
E-Selectin
10%
Vascular Cell Adhesion Molecule-1
9%
Safety
9%
Intercellular Adhesion Molecule-1
8%
Matrix Metalloproteinase 2
8%
Matrix Metalloproteinase 9
8%
Cell Movement
7%
Therapeutics
7%
Macrophages
6%
Leukemia, Myeloid, Chronic Phase
5%